$IVBXF

Innovent Biologics (01801.HK) and Daiichi Sankyo (4568) signed an exclusive China commercialization agreement for Vanflyta (quizartinib). Daiichi will handle development, manufacturing and supply, while Innovent has sole commercialization and promotion rights in China. Vanflyta was approved in China in June 2026 for newly diagnosed FLT3-ITD positive AML, based on QuANTUM-First.

Innovent Biologics said it signed an exclusive licensing deal with Spero Therapeutics for IBI355, an anti-CD40L antibody for autoimmune diseases. Innovent will get an upfront payment plus development, regulatory and commercial milestones totaling up to about $1.1 billion, and tiered royalties. Spero gets worldwide rights excluding Greater China. IBI355 is in Phase 1 and Phase 2 plans.

Innovent Biologics (01801.HK) and Spero Therapeutics (SPRO) announced an exclusive global license for IBI355 (SP001), an anti-CD40L antibody, with Spero holding rights worldwide excluding Greater China. Innovent will receive an upfront payment and milestones totaling about $1.1B plus tiered royalties. Spero plans Phase 2 in IgG4-RD in Q2 2027 and Innovent Phase 2 in China for Sjögren’s by early 2027.

Innovent Biologics said updated Phase 1 PoC data for IBI363, a PD-1/IL-2a bispecific fusion protein, showed positive efficacy in immunotherapy-resistant advanced NSCLC. In 136 patients, including 67 squamous and 58 EGFR wild-type adenocarcinoma, median PFS/OS at 3 mg/kg Q3W were 10.1/18.2 months (24-month OS 47.8%) and 4.2/15.2 months (24-month OS 42.7%). Safety was manageable, according to the company. IBI363 is co-developed with Takeda.